Oberlender, R; Nichols, DE. Structural variation and (+)-amphetamine-like discriminative stimulus properties. Pharmacol. Biochem. Behav., 1 Mar 1991, 38 (3), 581–586. 586 kB. https://doi.org/10.1016/0091-3057(91)90017-V
Cannon, JG; Perez, JA; Pease, JP; Long, JP; Flynn, JR; Rusterholz, DB; Dryer, SE. Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene. J. Med. Chem., 1 Jan 1980, 23 (7), 745–749. 731 kB. https://doi.org/10.1021/jm00181a009 #3a
Hyperlab. Hyperlab new compounds. 29 Sep 2014. 232 kB. Note: Contains links to hyperlab.info that require elevated access/karma to follow.
Kavanagh, PV; Power, JD. New psychoactive substances legislation in Ireland – Perspectives from academia. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 884-891. 1.2 MB. https://doi.org/10.1002/dta.1598
Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1 Jan 1994; pp 3–41. 8.1 MB. #8
Simmler, LD; Liechti, ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 143-164. 298 kB. https://doi.org/10.1007/164_2018_113
Seto, T; Takahashi, M; Nagashima, M; Suzuki, J; Yasuda, I. The identifications and the aspects of the commercially available uncontrolled drugs purchased between Apr. 2003 and Mar. 2004. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2005, 56 75–80. 1.2 MB. #2AI MS,NMR,UV
EMCDDA. New drugs in Europe, 2006, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2007. 375 kB. #2-aminoindan
Nichols, DE. CNS Stimulants. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 89–120. 1.8 MB. https://doi.org/10.1002/0471266949.bmc243 #23
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Aminoindanes 2-AI
Halberstadt, AL; Brandt, SD; Walther, D; Baumann, MH. 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors. Psychopharmacology, 1 Mar 2019, 236 (3), 989-999. 541 kB. https://doi.org/10.1007/s00213-019-05207-1 #2-AI
Manier, SK; Felske, C; Eckstein, N; Meyer, MR. The metabolic fate of two new psychoactive substances — 2‐aminoindane and N‐methyl‐2‐aminoindane — studied in vitro and in vivo to support drug testing. Drug Test. Anal., 25 Nov 2019, 12 (1), 145-151. 1.2 MB. https://doi.org/10.1002/dta.2699 #2-AI MS
Simmler, LD; Rickli, A; Schramm, Y; Hoener, MC; Liechti, ME. Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem. Pharmacol., 15 Mar 2014, 88 (2), 237–244. 504 kB. https://doi.org/10.1016/j.bcp.2014.01.024 #2-AI
Antonides, LH; Brignall, RM; Costello, A; Ellison, J; Firth, SE; Gilbert, N; Groom, BJ; Hudson, SJ; Hulme, MC; Marron, J; Pullen, ZA; Robertson, TBR; Schofield, CJ; Williamson, DC; Kemsley, EK; Sutcliffe, OB; Mewis, RE. Rapid identification of novel psychoactive and other controlled substances using low-field 1H NMR spectroscopy. ACS Omega, 30 Apr 2019, 4 (4), 7103–7112. 1.3 MB. https://doi.org/10.1021/acsomega.9b00302 #2-Aminoindane NMR
Kikura-Hanajiri, R; Kawamura, M; Uchiyama, N; Ogata, J; Kamakura, H; Saisho, K; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part I: GC-MS and LC-MS. Yakugaku Zasshi, 1 Jun 2008, 128 (6), 971–979. 1.4 MB. https://doi.org/10.1248/yakushi.128.971 #2-Aminoindan Incorrect structures drawn. Corrected structures in errata page at end. GC,LC,MS,UV
Uchiyama, N; Kawamura, M; Kamakura, H; Kikura-Hanajiri, R; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part II: Color test and TLC. Yakugaku Zasshi, 1 Jan 2008, 128 (6), 981–987. 406 kB. https://doi.org/10.1248/yakushi.128.981 #2-aminoindan TLC
Nahoko, U; Ruri, K; Nobuo, K; Yukihiro, G. Analysis of designer drugs detected in the products purchased in fiscal year 2006. Yakugaku Zasshi, 1 Jan 2008, 128 (10), 1499–1505. 604 kB. https://doi.org/10.1248/yakushi.128.1499 #Indan-2-amine GC,LC,MS,NMR